Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Antibiotics (Basel) ; 11(1)2022 Jan 11.
Article in English | MEDLINE | ID: mdl-35052960

ABSTRACT

Chronic bacterial prostatitis is increasingly difficult to treat due to rising antimicrobial resistance limiting oral treatment options. In this case series, 11 men with CBP (including patients with urological comorbidities) due to multi-resistant E. coli were treated with once-daily ceftriaxone intravenously for 6 weeks. Nine patients were clinically cured at 3 months follow up. No early withdrawal of medication due to side effects occurred. A literature review was conducted to describe the prostate pharmacokinetics of ceftriaxone and its use in prostatic infection. In conclusion, ceftriaxone can be considered an appropriate treatment of chronic bacterial prostatitis.

2.
World J Urol ; 28(1): 3-8, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19816692

ABSTRACT

PURPOSE: Previous studies on associations between voiding dysfunction and quality of life (QoL) have largely been limited to baseline data. Therefore, we have explored associations between Q (max) and voiding and storage sub-scores of the International Prostate Symptom Score (IPSS) before and after treatment with QoL. METHODS: Analysis of a single-center database of 2,316 men with voiding dysfunction attributed to benign prostatic hyperplasia undergoing various medical and surgical treatment forms. RESULTS: Q (max) exhibited little correlation with QoL before or after treatment. IPSS inversely correlated with QoL at baseline and after treatment, and IPSS improvements correlated with those of QoL. The associations applied to both the voiding and storage sub-score of the IPSS, with the latter consistently exhibiting somewhat tighter associations. CONCLUSIONS: Our post-treatment data support the idea of a cause-effect relationship between voiding symptoms and QoL irrespective of treatment form. While both voiding and storage symptoms contribute to this relationship, storage symptoms play a somewhat greater role.


Subject(s)
Prostatic Hyperplasia/complications , Prostatic Hyperplasia/therapy , Quality of Life , Urination Disorders/etiology , Aged , Humans , Male , Middle Aged , Prostatic Hyperplasia/physiopathology , Retrospective Studies , Urination Disorders/diagnosis , Urination Disorders/physiopathology
3.
BJU Int ; 105(8): 1141-6, 2010 Apr.
Article in English | MEDLINE | ID: mdl-22299137

ABSTRACT

OBJECTIVES: To determine the role of treatment-associated improvement in nocturia in health-related quality of life (HRQL) in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia, and secondarily to confirm the role of nocturia in HRQL at baseline and to compare the effects of watchful waiting, transurethral microwave treatment (TUMT) and transurethral resection of the prostate (TURP) to those of α1-adrenoceptor antagonists (α-blockers) on nocturia. PATIENTS AND METHODS: We retrospectively analysed using multiple regression a large single-centre database of patients receiving routine care for treatment-associated alterations of symptoms and HRQL (assessed at baseline, 2611 men) and 6-12 months after initiation of treatment (1258 men). RESULTS: Among the symptoms assessed using the International Prostate Symptom Score, nocturia (together with urgency and weak stream) had the strongest correlation with HRQL at baseline and after treatment. Watchful waiting, α-blockers, TUMT and TURP reduced nocturia episodes by a mean (sd) of 7 (53)%, 17 (40)%, 32 (47)% and 75 (23)%, respectively. The treatment-associated improvements in nocturia (together with those of weak stream) had the strongest association with those of HRQL. CONCLUSIONS: We conclude that among all LUTS assessed in the IPSS, nocturia has one of the strongest associations with HRQL, and that treatment-associated improvements in nocturia contribute considerably to overall improvements in HRQL.


Subject(s)
Lower Urinary Tract Symptoms/therapy , Nocturia/therapy , Prostatic Hyperplasia/therapy , Quality of Life , Adrenergic alpha-1 Receptor Antagonists/therapeutic use , Aged , Humans , Male , Middle Aged , Multivariate Analysis , Retrospective Studies , Transurethral Resection of Prostate , Watchful Waiting
4.
J Endourol ; 21(7): 709-13, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17705755

ABSTRACT

BACKGROUND AND PURPOSE: On the one hand, nephron-sparing surgery (NSS) in small renal tumors is a safe and effective alternative to radical nephrectomy. On the other hand, the role of preoperative percutaneous needle biopsies (PNB) remains controversial. The purpose of this study was to evaluate the global current use of NSS in the treatment of renal-cell carcinoma (RCC) and the use of PNB among endourologists. MATERIALS AND METHODS: One thousand questionnaires were distributed during the 23rd World Congress of Endourology and SWL. Six questions regarding NSS and two questions regarding PNB were presented. Two hundred twenty-two questionnaires were returned. RESULTS: Of the respondents, 86.6% perform NSS for small renal tumors, whereas 13.4% perform only radical nephrectomies; 7.5% will consider NSS only in patients with a solitary kidney, and 0.5% will never consider NSS. The techniques for NSS, in descending order of preference, are partial nephrectomy, enucleation, cryoablation, radiofrequency ablation, and high-intensity focused ultrasound. The mean and maximum diameter of the tumor in patients with a normal contralateral kidney for which the urologists perform NSS is 4.0 cm. For a centrally located tumor, NSS is an option for 27.2% of the respondents. Regarding PNB in patients with suspicion of RCC, 55.9% of respondents never obtain renal biopsies in the preoperative assessment and 41.8% obtain them only in rare cases. The majority (90%) prefer histologic over cytologic biopsies. CONCLUSIONS: Nephron-sparing surgery is evolving to a global worldwide standard treatment for small renal tumors. Percutaneous needle biopsy remains a highly debated procedure.


Subject(s)
Carcinoma, Renal Cell/surgery , Health Care Surveys , Kidney Neoplasms/surgery , Nephrons , Physicians , Surveys and Questionnaires , Urology/methods , Biopsy , Carcinoma, Renal Cell/pathology , Humans , Kidney Neoplasms/pathology , Nephrons/surgery
5.
Drugs ; 66(3): 287-301, 2006.
Article in English | MEDLINE | ID: mdl-16526818

ABSTRACT

alpha(1)-Adrenoceptor antagonists such as alfuzosin, doxazosin, tamsulosin and terazosin are first-line agents for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH), but are only second-line agents (doxazosin and terazosin only) for the treatment of arterial hypertension. Sexual function is complex and includes multiple domains such as sexual desire (libido), erectile function and ejaculatory function. Erectile and ejaculatory functions are frequently reduced in patients with BPH and can impact on their quality of life. Therefore, the treatment of BPH should aim to maintain or even restore sexual function.alpha(1)-Adrenoceptor antagonists lack major effects on sexual desire in placebo-controlled studies. Reports on erectile function are inconsistent, with both beneficial and adverse effects being reported, but impotence can occur in some patients without clear differences between drugs. Ejaculatory dysfunction during treatment may represent (relative) an ejaculation. It occurs more frequently with tamsulosin than with other drugs of this class, but the differences are not big enough to be consistently detectable in directly comparative studies. We propose that such differences between drugs should be weighed against differences in cardiovascular tolerability when choosing the optimal treatment for each patient.


Subject(s)
Adrenergic Antagonists/pharmacology , Adrenergic alpha-1 Receptor Antagonists , Ejaculation/drug effects , Libido/drug effects , Penile Erection/drug effects , Adrenergic Antagonists/adverse effects , Adult , Aged , Doxazosin/adverse effects , Doxazosin/pharmacology , Erectile Dysfunction/etiology , Humans , Male , Middle Aged , Prostatic Hyperplasia/drug therapy , Prostatic Hyperplasia/metabolism , Quinazolines/adverse effects , Quinazolines/pharmacology , Randomized Controlled Trials as Topic , Receptors, Adrenergic, alpha-1/metabolism , Sulfonamides/adverse effects , Sulfonamides/pharmacology , Tamsulosin
6.
Urology ; 66(4): 845-9, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16230150

ABSTRACT

OBJECTIVES: To assess the efficacy and safety of the thermoexpandable hourglass-shaped nitinol prostatic stent in the treatment of patients with lower urinary tract symptoms due to bladder outlet obstruction. METHODS: The stents were inserted in an outpatient setting under local anesthesia and direct vision. Five different stent lengths (2.0 to 4.0 cm) were used, depending on the length of the prostatic urethra. Assessment of voiding function and symptom scores was performed at baseline, directly after stent insertion, at 14 days, and 1, 3, 6, and 12 months after stent placement. RESULTS: We enrolled 35 men in the trial. In 5 patients, insertion of the stent failed, mainly because of anatomical limitations. After all placement procedures, minimal temporary hematuria was observed. Spontaneous voiding was achieved in all patients, with immediate significant improvements in voiding parameters and symptom scores. The median indwelling time of the stent was 70 days. Kaplan-Meier survival analysis showed that at 14 days and at 3, 6, and 12 months, the stent was still in situ in 73%, 40%, 33%, and 23% of the patients, respectively. The main reason for removal of the stent was migration (93%), in most cases toward the bladder. Removal was uneventful in all but 1 case. CONCLUSIONS: The placement of the thermoexpandable hourglass-shaped nitinol stent results in relief of outflow obstruction and improvement of symptom scores. Because of the high migration rate, however, this stent design needs further improvement to be suitable for clinical practice.


Subject(s)
Alloys , Stents , Urinary Bladder Neck Obstruction/surgery , Aged , Equipment Design , Humans , Male , Prospective Studies , Urinary Bladder Neck Obstruction/complications , Urination Disorders/etiology , Urination Disorders/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...